Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security
August 25, 2017
- MHLW Council Recommends Public Knowledge-Based Applications for 2 Products Including Velcade
August 25, 2017
- MHLW Presents Steps Responding to Chuikyo Reps’ Concerns for “Willing-to-Pay Cost” Survey
August 24, 2017
- Chuikyo OKs MHLW’s Discussion Timeline on CEA, 3 Subcommittees to Hold Joint Debates
August 24, 2017
- Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
- Leftover Spinraza in 9-Million-Yen Vial Must Be Discarded, Can’t Be Saved for Next Time: MHLW Official
August 23, 2017
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
- Final Report on MID-NET’s Full Operations Published
August 22, 2017
- MHLW Study Group to Expand Investigation to Clinics to Determine Causes of Improper Promotional Activities
August 22, 2017
- Clinical Research Law to Apply to Indirectly Funded Programs Too, MHLW to Clarify Procedures: Official
August 21, 2017
- MHLW Advisory Panel to Review Budesonide Rectal Foam on Sept. 1
August 21, 2017
- 11 Firms Get Approval for Irbesartan Generics towards December Listing, including AG; 26 Flock to Crestor
August 16, 2017
- NIBIOHN to Promote Drug Discovery in Fields with Unmet Needs by Automating Target Discovery Using AI
August 15, 2017
- “Pediatric Treatment” Excluded from Appraisal Adjustment Factors in Pilot Program: Chuikyo
August 10, 2017
- MHLW Wants to Use Past Surveys, Overseas Examples for ICER Yardstick in CEA Pilot Program, Plan Draws Fire from Payers Reps: Chuikyo
August 10, 2017
- Calls Growing for Tougher Requirements to Receive Price Maintenance Premium: Chuikyo
August 10, 2017
- New Measures Needed to Ramp Up Generic Use: Chuikyo
August 10, 2017
- MHLW Orders Label Revisions for Warfarin, 3 Other APIs
August 7, 2017
- (Update) Katsunobu Kato Tapped as New Health Minister
August 4, 2017
- Clinical Research Law to Apply to “Nearly All Drug-Related Clinical Research” Funded by Drug Makers: MHLW
August 4, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…